Moximed
PrivateLast Round
Series D
Aug 13, 2024
Total Funding Raised
$219M
Company Overview
Moximed is a medical device company that develops unicompartmental load absorber implants designed to enhance the treatment of osteoarthritis by reducing joint pain and potentially delaying the need for more invasive surgeries.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Moximed Comparables
Compare Moximed with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hyalex Orthopaedics | 77% | |
| Vitalis Ortho | 72% | |
| Arthrex | 71% |
Moximed Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 13, 2024 | ||||
| Debt | Aug 16, 2022 | ||||
| Debt | Jul 14, 2022 | ||||
| Series C | Mar 15, 2017 | ||||
| Series B | May 7, 2015 | ||||
VC Round | Jun 30, 2011 |
Moximed Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Runway Growth Capital | Debt |
| Frazier Healthcare Partners | VC Round |
| Vertex Ventures HC | Series D |
| New Enterprise Associates | Series D, Debt, Series B, Series A, VC Round, Series C |
| Cormorant Asset Management | Series D |
| Future Fund | Debt, Series D, Series C |
| Advent Life Sciences | Series D, Series C, Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2026
MISHA Knee System received FDA clearance for market.
- Feb 10, 2026
Launched the MISHA Knee System, an implantable shock absorber for knee osteoarthritis.
Moximed Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Moximed's valuation, stock price, and market status.
Is Moximed a public or private company?
Moximed is a private company.
What is the current stock price of Moximed?
Moximed is a private company with no public stock price. No recent secondary market data is available.
How much is Moximed worth (valuation)?
Valuation information for Moximed is not publicly available.
Can I buy Moximed stock?
Moximed shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Moximed's last funding round?
Moximed's most recent funding round was Series D on August 13, 2024.
Who are the main investors in Moximed?
Key investors in Moximed include Runway Growth Capital, Future Fund, Advent Life Sciences, Vertex Ventures US, Cormorant Asset Management.
Will Moximed IPO soon?
No public IPO plans have been announced for Moximed.
How can I track Moximed secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Moximed's secondary market activity and sign up for updates.